Skip to main content
Erschienen in: International Urology and Nephrology 9/2022

02.03.2022 | Nephrology - Original Paper

Incidence and mortality of acute kidney disease following coronary angiography: a cohort study of 9223 patients

verfasst von: Jin Liu, Qiang Li, Weihua Chen, Haozhang Huang, Yaren Yu, Bo Wang, Guoxiao Liang, Wenguang Lai, Liwei Liu, Ming Ying, Haiyan Wei, Zhigang Huang, Jindong Ni, Jiyan Chen, Shiqun Chen, Yong Liu

Erschienen in: International Urology and Nephrology | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Acute kidney disease (AKD) is an important state in the evolving kidney diseases. However, there is limited data on the incidence and prognosis of AKD following coronary angiography (CAG). Therefore, we aim to characterize the incidence and prognosis of AKD across a large population of CAG patients.

Methods

The consecutive patients with baseline and following measurement of serum creatinine (Scr) between 7 and 90 days after CAG procedure were included. The AKD was defined as a decrease in glomerular filtration rate by > 35%, or an increase in Scr of > 50% (from 7 to 90 days). Survival curves, univariate and multivariable cox regressions were used to assess the association between AKD and mortality.

Results

Among 9223 patients (male, 60.3%, mean age, 61.7 ± 9.6), 1540 had AKD. During a median follow-up of 5.4 (IQR 2.2–8.6) years, 1562 (16.9%) patients died. The mortality among the patients with AKD was higher than the non-AKD group (24.8% vs. 15.4%, p < 0.001). AKD was independently associated with a significantly increased risk of all-cause mortality (adjusted hazard ratio [aHR], 1.57; 95% CI 1.39–1.78; p < 0.001).

Conclusions

Our study suggested that AKD is commonly observed after CAG and increased half mortality risk than those without AKD. More attention needs to be paid to patients suffering from AKD.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
12.
Zurück zum Zitat Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr et al (2012) 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 60(7):645–681. https://doi.org/10.1016/j.jacc.2012.06.004CrossRefPubMed Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr et al (2012) 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 60(7):645–681. https://​doi.​org/​10.​1016/​j.​jacc.​2012.​06.​004CrossRefPubMed
13.
Zurück zum Zitat Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM et al (2009) 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 54(23):2205–2241. https://doi.org/10.1016/j.jacc.2009.10.015CrossRefPubMed Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM et al (2009) 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 54(23):2205–2241. https://​doi.​org/​10.​1016/​j.​jacc.​2009.​10.​015CrossRefPubMed
14.
Zurück zum Zitat Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B et al (2016) 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: an Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. J Am Coll Cardiol 67(10):1235–1250. https://doi.org/10.1016/j.jacc.2015.10.005CrossRefPubMed Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B et al (2016) 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: an Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. J Am Coll Cardiol 67(10):1235–1250. https://​doi.​org/​10.​1016/​j.​jacc.​2015.​10.​005CrossRefPubMed
Metadaten
Titel
Incidence and mortality of acute kidney disease following coronary angiography: a cohort study of 9223 patients
verfasst von
Jin Liu
Qiang Li
Weihua Chen
Haozhang Huang
Yaren Yu
Bo Wang
Guoxiao Liang
Wenguang Lai
Liwei Liu
Ming Ying
Haiyan Wei
Zhigang Huang
Jindong Ni
Jiyan Chen
Shiqun Chen
Yong Liu
Publikationsdatum
02.03.2022
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 9/2022
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-022-03110-x

Weitere Artikel der Ausgabe 9/2022

International Urology and Nephrology 9/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.